skip to content
Primary navigation


DrugAlecensa® (alectinib) [Genentech, Inc.]

December 2017

Therapeutic area - Oncology

Approval criteria

  • Patient must be 18 years of age or older AND
  • Patient must have a diagnosis of anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test

Quantity limit

Maximum of 240 capsules per 30 days.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top